8/9/2019 2013 Investor Fact Sheet

1/2

2013

D e s c r i p t i o n• Through its family of companies, the world’s most comprehensive and

broadly based manufacturer of health care products• Serves the Consumer, Pharmaceutical and Medical Devices and

Diagnostics markets by developing broadly accessible, high quality,innovative products and services that advance the health and well-beingof people

Co n s i s t en t P er f o r m a n c e• 30 consecutive years of earnings increases adjusted for special items• 51 consecutive years of dividends increases

One Year 2 Five Years 2 Ten Years 2 Sales 6.1% 2.3% 5.5%Diluted Adjusted Earnings perShare 1

8.2% 3.9% 8.1%

Dividend Growth 7.9% 7.6% 10.8%Total Return to Shareholders 34.6% 12.6% 8.9%1 Non-GAAP, excludes special items. Reconciliation available in corresponding Annual Reports.2 Compounded Annual Growth Rates

B r o a d l y B a s ed / E x cep t i o n a l F i n a n c i a l St r en g t h• Over 275 operating companies in 60 countries selling products

throughout the world (approximately 55% of sales outside of U.S.) • Sales split among Consumer, Pharmaceutical and Medical Devices and

Diagnostics business segments • More than 100 drugs marketed; 41 drugs over $50 million; 32 drugs over

$100 million; 8 drugs over $1 billion • One of four U.S. industrial companies that still commands a Triple A

credit rating by both Standard & Poor’s and Moody’s credit ratingagencies

• Generated annual free cash flow 1 in 2013 of $13.8 billion.

1Non-GAAP financial measure; defined as operating cash flow less capital spending

(1) Net Earnings attributable to Johnson & Johnson

W o r l d w i d e M a r k et L ea d er s h i p• Largest Medical Device company • 7th largest Pharmaceutical company

globally • 6 th largest Biotech company globally • 6 th largest Consumer Health Care

company globally • Leadership Positions in Major Markets:

• Antithrombotic agents • Antipsychotics (Injectables)• Anti - TNF • Baby Care • Biosurgicals • Blood Glucose Monitoring • Breast Aesthetics • Disposable Contact Lenses • Electrophysiology diagnostics

& catheters • Hormone antagonists • Infection Prevention • Lo-Cal Sweeteners • Minimally Invasive Surgery • Oral Rinses • Orthopaedics • OTC Analgesics •

Sanitary Protection • Sutures • Systemic Antipsoriasis

products • Wound Care

• Approximately 70% of sales are derivedfrom products/businesses that have a#1 or #2 global market share position

2013 WorldwideSales $71.3 Billion

2013InvestorFact Sheet

App roxim atel y##%

Please visit our Home Page on the Internet athttp://www.jnj.com for requests for CompanyReports , including the 2013 Annual Reportand SEC filings. Questions regarding stockholdings and the Dividend ReinvestmentPlan , should be directed to: Computershare

T C N A Ph (800) 328 9033

2003

$6,848

2008

Net Earnings (1) (as r eported) $U.S. Millions $12,949

$13,831

App roxim atel y25%

New Products Introducedin Past 5 Years

8/9/2019 2013 Investor Fact Sheet

2/2

St r o n g Co m m i t m en t t o N ewP r o d u c t D ev e lo p m en t• $8.2 billion in Research &

Development expense in 2013• Numerous external alliances and

collaborations entered intoannually

• Approximately 25% of productssold in 2013 introduced in last 5 years

M a n a g e m e n t B a s ed o n a C o r e Seto f St r a t e g i c Pr i n c i p l es

• Creating Value through Innovationo Robust pipeline of new and

innovative products• Global Reach/Local Focus

o Broad geographic reachprovides ability to rapidlyintroduce new products inmarkets around the world

• Excellence in Executiono Maintaining high quality

products and standards• Leading with a Purpose

o Focus on products whichincrease access, reduce cost andimprove the quality of healthcare

I n v e st o r I n f o r m a t i o n

N Y SE Sy m b o l : J N J

F o r a d d i t i o n a l i n f or m a t i o n ,contact:Investor Relations DepartmentOne Johnson & Johnson PlazaNew Brunswick, NJ 08933

Voice: (800) 950-5089Fax: (732) 524-3867

P r e ss r e l e a s es , including earningsreports, are available via web access:http://www.jnj.com

$18.6

$7.4

$13.4

$31.9

80

105130

155

180205

230

2003 2005 2007 2009 2011 2013

D O L L A R S

Johnson & Johnson

S&P 500

S&P Pharm

S&P H/C Equip

2013 Sales by Geographic Ar ea$U.S. Billions

Shareholder Return Comparison$100 Dollars invested December 31, 2003

This chart provides a comparison of cumulative total shareholder return for aninvestment in Johnson & Johnson Common Stock as of December 31, 2013 to a similarinvestment in the identified indices. Assuming dividends were reinvested, a $100.00investment in Johnson & Johnson would have grown to $235.59 as of December 31, 2013.This compares to a value of $204.26 for the S&P 500 Stock Index, $193.25 for the S&P Pharmaceutical Index and $166.10 for the S&P Healthcare Equipment Index. Source: Bloomberg

Europe

U.S.

WesternHemisphere

Asi a-Pacif ic Afr ica

45%

26%

10%

19%

$28.5

$28.1

$14.7

2013 Sales by Segment$U.S. Billions

21% 40%

39%

MD&D

Pharmaceutical

Consumer

International

U.S.

Net Trade Sales$U.S. Billions

2003 2008 2013

© Johnson & Johnson 2013

$71.3

$63.7

$41.9